Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

Clinical and Translational Oncology

Volumn 11, Issue 11, 2009, Pages 727-736

  Alberola Candel, Vicente ^a   Carrato Mena, Alfredo ^b   Díaz Rubio García, Eduardo ^c   Gascón Vilaplana, Pere ^d   González Barón, Manuel ^e   Martín Jiménez, Miguel ^c   Alba Conejo, Emilio ^f   Cassinello Espinosa, Javier ^g   Colomer, Ramon ^h   Cruz Hernández, Juan Jesús ⁱ   Barnadas I Molins, Agustí ^j   Camps Herrero, Carlos ^k   Casas Fernández De Tejerina, Ana Ma ^l   Carulla Torrent, Joan ^m   Constenla Figueiras, Manuel ⁿ   Gavilá Gregori, Joaquin ^k   Isla Casado, Ma Dolores ^o   Massuti Sureda, Bartomeu ^p   Provencio Pulla, Mariano ^q   Rodríguez Sánchez, César Augusto ⁱ   Sanz Ortiz, Jaime ^r   more..

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^h MD ANDERSON CANCER CENTER   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^m Hospital Mateu Orfila   (Spain)

ⁿ HOSPITAL MONTECELO   (Spain)

^o HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^q HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^r HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

Cancer associated anaemia; Chemotherapy; Consensus; Erythropoietic stimulating agents; Update

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ASTHENIA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON THERAPY; LUNG CANCER; MEDICAL SOCIETY; OVERALL SURVIVAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; THROMBOSIS;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; ERYTHROCYTES; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SPAIN;

EID: 73449117184     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0435-6     Document Type: Review

References (97)

1. H. Ludwig S. Van Belle P. Barrett-Lee, et al. 2004 The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients Eur J Cancer 40 2293 2306 10.1016/j.ejca.2004.06.019 15454256 (Pubitemid 39348881)
2. J.E. Groopman L.M. Itri 1999 Chemotherapy-induced anemia in adults: incidence and treatment J Natl Cancer Inst 91 1616 1634 10.1093/jnci/91.19.1616 1:CAS:528:DyaK1MXmvVyntbc%3D 10511589
3. J. Crawford D. Cella C.S. Cleeland, et al. 2002 Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 888 895 10.1002/cncr.10763 1:CAS:528:DC%2BD38Xms1Shuro%3D 12209734 (Pubitemid 34839682)
4. American Society of Clinical Oncology 1996 Outcomes of cancer treatment for technology assessment and cancer treatment guidelines J Clin Oncol 14 671 679
5. P. Gascón 2005 Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting Eur J Cancer 41 2601 2612 10.1016/j.ejca.2005.04.046 16230006 (Pubitemid 41607551)
6. H. Ludwig E. Fritz H. Kotzmann, et al. 1990 Erythropoietin treatment of anemia associated with multiple myeloma N Engl J Med 322 1693 1699 1:STN:280:DyaK3c3lvFSgsw%3D%3D 2342535 (Pubitemid 20231526)
7. G.D. Demetri M. Kris J. Wade, et al. 1998 Qualityof-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study J Clin Oncol 16 3412 3425 1:CAS:528:DyaK1cXmvFGrur0%3D 9779721
8. J.L. Gabrilove C.S. Cleeland R.B. Livingston, et al. 2001 Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2875 2882 1:CAS:528:DC%2BD3MXltVGgs7Y%3D 11387360
9. D. Shasha M.J. George L.B. Harrison 2003 Onceweekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy Cancer 98 1072 1079 10.1002/cncr.11616 1:CAS:528: DC%2BD3sXns1Sjsbk%3D 12942577 (Pubitemid 37022110)
10. I. Quirt C. Robeson C.Y. Lau, et al. 2001 Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy J Clin Oncol 19 4126 4134 1:CAS:528:DC%2BD3MXosFSmtb8%3D 11689580
11. J.H. Savonije C.J. van Groeningen L.W. Wormhoudt G. Giaccone 2006 Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level Oncologist 11 206 216 10.1634/theoncologist.11-2-206 1:CAS:528:DC%2BD28XhtFKqsbvL 16476841 (Pubitemid 43261767)
12. A. Bamias G. Aravantinos C. Kalofonos, et al. 2003 Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group Oncology 64 102 110 10.1159/000067766 1:CAS:528:DC%2BD3sXntFSitA%3D%3D 12566906 (Pubitemid 36173373)
13. D.H. Henry 2007 Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies Drugs 67 175 194 10.2165/00003495-200767020-00002 1:CAS:528:DC%2BD2sXksFOjsLo%3D 17284083 (Pubitemid 46257306)
14. S. Cascinu A. Fedeli E. Del Ferro, et al. 1994 Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo J Clin Oncol 12 1058 1062 1:STN:280: DyaK2c3hs12htA%3D%3D 8164030
15. D.H. Henry B.J. Brooks Jr D.C. Case Jr, et al. 1995 Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy Cancer J Sci Am 1 252 260 1:STN:280:DC%2BD28rmsFyjsw%3D%3D 9166485
16. T.E. Witzig P.T. Silberstein C.L. Loprinzi, et al. 2005 Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy J Clin Oncol 23 2606 2617 10.1200/JCO.2004.10. 020 1:CAS:528:DC%2BD2MXktleqsbc%3D 15452187 (Pubitemid 46179449)
17. J. Chang F. Couture S. Young, et al. 2005 Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy J Clin Oncol 23 2597 2605 10.1200/JCO.2004.12. 027 1:CAS:528:DC%2BD2MXktleqsbY%3D 15452188 (Pubitemid 46179448)
18. S.N. Scott T.J. Boeve T.M. McCulloch, et al. 2002 The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study Laryngoscope 112 1221 1229 10.1097/00005537-200207000-00015 1:CAS:528:DC%2BD38XlvVSnsrs%3D 12169903
19. T.J. J Littlewood E. Bajetta J.W. Nortier, et al. 2001 Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2865 2874
20. P.M. Wilkinson M. Antonopoulos M. Lahousen, et al. 2006 Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial Br J Cancer 94 947 954 10.1038/sj.bjc.6603004 1:CAS:528:DC%2BD28XjtFGqtrc%3D 16570051
21. R.I. Abels K.M. Larholt K.D. Krantz E.C. Bryant 1996 Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer Oncologist 1 140 150 1:CAS:528:DyaK1cXlvF2htbY%3D 10387980
22. F. Dammacco G. Castoldi S. Rödjer 2001 Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma Br J Haematol 113 172 179 10.1046/j.1365-2141.2001.02715.x 1:CAS:528:DC%2BD3MXkt1SjsLw%3D 11328297 (Pubitemid 32423318)
23. C. Kurz C. Marth G. Windbichler, et al. 1997 Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study Gynecol Oncol 65 461 466 10.1006/gyno.1997.4675 1:CAS:528:DyaK2sXktF2itrY%3D 9190976 (Pubitemid 27255989)
24. H. Kunikane K. Watanabe M. Fukuoka, et al. 2001 Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with nonsmall cell lung cancer Int J Clin Oncol 6 296 301 10.1007/s10147-001-8031-y 1:CAS:528:DC%2BD38Xhtlykt78%3D 11828949 (Pubitemid 34137231)
25. R. Pirker M. Lehnert W. Minar 2007 Onceweekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy Lung Cancer 55 89 94 10.1016/j.lungcan.2006.09.020 17084484 (Pubitemid 46038883)
26. C. Oberhoff B. Neri D. Amadori, et al. 1998 Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study Ann Oncol 9 255 260 10.1023/A:1008296622469 1:STN:280:DyaK1c3msV2lug%3D%3D 9602258 (Pubitemid 28186794)
27. M. Boogaerts C. Oberhoff W. Ten Bokkel Huinink, et al. 2006 Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis Anticancer Res 26 479 484 1:CAS:528:DC%2BD28Xhs1aiu7c%3D 16739308
28. J. Vansteenkiste R. Pirker B. Massuti, et al. 2002 Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 1211 1220 1:CAS:528:DC%2BD38XntVyjs7c%3D 12189224
29. D. Kotasek G. Steger W. Faught, et al. 2003 Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study Eur J Cancer 39 2026 2034 10.1016/S0959-8049(03)00456-8 1:CAS:528: DC%2BD3sXmvVKgt78%3D 12957457 (Pubitemid 37297759)
30. M. Hedenus M. Adriansson J. San Miguel, et al. 2003 Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebocontrolled study Br J Haematol 122 394 403 10.1046/j.1365-2141.2003.04448.x 1:CAS:528:DC%2BD3sXmvFyns7o%3D 12877666 (Pubitemid 36951623)
31. J. Bohlius S. Langensiepen G. Schwarzer, et al. 2005 Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis J Natl Cancer Inst 97 489 498 1:CAS:528: DC%2BD2MXjtFalt7w%3D 15812074
32. J. Bohlius J. Wilson J. Seidenfeld, et al. 2006 Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 708 714 1:CAS:528: DC%2BD28XkvVSrs70%3D 16705125
33. C. Bokemeyer M.S. Aapro A. Courdi, et al. 2007 EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update Eur J Cancer 43 258 270 10.1016/j.ejca.2006.10.014 1:CAS:528:DC%2BD2sXpvVKrsg%3D%3D 17182241 (Pubitemid 46127840)
34. A. Östeborg M.A. Boogaerts R. Cimino, et al. 1996 Recombinant human erythropoietin, epoetin beta in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study Blood 87 2675 2682
35. M. Bogaaerts B. Coiffer C. Kainz 2003 Impact of epoetin beta in quality of life in patients with malignant disease Br J Cancer 88 988 995 10.1038/sj.bjc.6600801 (Pubitemid 36560764)
36. J. Seidenfeld M. Piper C. Flamm, et al. 2001 Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials J Natl Cancer Inst 93 1204 1214 10.1093/jnci/93.16. 1204 1:CAS:528:DC%2BD3MXms1OrtLY%3D 11504766
37. J.D. Rizzo A.E. Lichtin S.H. Woolf, et al. 2002 Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J Clin Oncol 20 4083 4107 10.1200/JCO.2002.07.177 1:CAS:528:DC%2BD38XntF2js7s%3D 12351606
38. G. Iconomou A. Koutras A. Rigopoulos, et al. 2003 Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial J Pain Symptom Manage 25 512 518 10.1016/S0885-3924(03)00070-8 1:CAS:528:DC%2BD3sXlsFejt7w%3D 12782431 (Pubitemid 36629274)
39. Bohlius J, Langensiepen S Schwarzer G et al (2005) Erythropoietin for patients with malignant disease. Cochrane Libr 4
40. P. Barrett-Lee C. Bokemeyer P. Gascón, et al. 2005 Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey Oncologist 10 743 757 10.1634/theoncologist.10-9-743 1:CAS:528:DC%2BD2MXht1CgsL7J 16249356 (Pubitemid 41567288)
41. J. Patton T. Reeves J. Wallace 2004 Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice Oncologist 9 451 454 10.1634/theoncologist.9-4-451 1:CAS:528:DC%2BD2cXntV2rsr4%3D 15266098 (Pubitemid 39014556)
42. D. Cella E.A. Hahn K. Dineen 2002 Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening Qual Life Res 11 207 221 10.1023/A:1015276414526 12074259 (Pubitemid 34553502)
43. J. Glaspy R. Bukowski D. Steinberg, et al. 1997 Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice Procrit Study Group. J Clin Oncol 15 1218 1234 1:CAS:528:DyaK2sXitFCgsLY%3D
44. H.S. Wu M. McSweeney 2004 Assessing fatigue in persons with cancer: an instrument development and testing study Cancer 101 1685 1695 10.1002/cncr.20540 15378502 (Pubitemid 39318918)
45. D.M. Hann P.B. Jacobsen L.M. Azzarello, et al. 1998 Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory Qual Life Res 7 301 310 10.1023/A:1008842517972 1:STN:280: DyaK1c3ntlWgtg%3D%3D 9610214 (Pubitemid 28207019)
46. P. Gascón J. García-Mata R. Colomer, et al. 2007 Final results of the validation of the PERFORM Questionnaire, a new questionnaire to assess the patient perception of cancer-related fatigue Eur J Cancer [Suppl4] 1159
47. J. Glaspy D. Henry R. Patel, et al. 2005 Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa Eur J Cancer 41 1140 1149 10.1016/j.ejca.2005.01.021 1:CAS:528:DC%2BD2MXks1Gjtrw%3D 15911237 (Pubitemid 40725572)
48. P.J. Hesketh F. Arena D. Patel, et al. 2004 A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies Cancer 100 859 868 10.1002/cncr.11954 1:CAS:528:DC%2BD2cXhvF2qur8%3D 14770445 (Pubitemid 38176867)
49. D.C. Case Jr R.M. Bukowski R.W. Carey, et al. 1993 Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy J Natl Cancer Inst 85 801 806 10.1093/jnci/85.10.801 8487324
50. F. Silvestris A. Romito P. Fanelli, et al. 1995 Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma Ann Hematol 70 313 318 10.1007/BF01696618 1:CAS:528:DyaK2MXosVChsro%3D 7632811
51. B. Leyland-Jones V. Semiglazov M. Pawlicki, et al. 2005 Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study J Clin Oncol 23 5960 5972 10.1200/JCO.2005.06.150 1:CAS:528:DC%2BD2MXhtVKgtb3M 16087945 (Pubitemid 46300213)
52. (2007) Cancer and treatment-related anemia. NCCN Practice guidelines in Oncology, v2
53. J. Glaspy L. Degos M. Dicato G.D. Demetri 2002 Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials Oncologist 7 126 135 10.1634/theoncologist.7-2-126 1:CAS:528:DC%2BD38XlsF2ntb0%3D 11961196 (Pubitemid 34438541)
54. W.W. ten Bokkel Huinink C.A. de Swart D.W. van Toorn, et al. 1998 Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy Med Oncol 15 174 182 10.1007/BF02821936 9819794
55. M. Cazzola Y. Beguin J. Kloczko, et al. 2003 Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production Br J Haematol 122 386 393 10.1046/j.1365-2141.2003.04439.x 1:CAS:528:DC%2BD3sXmvFyns70%3D 12877665 (Pubitemid 36951622)
56. J.L. Canon J. Vansteenkiste G. Bodoky, et al. 2006 Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia J Natl Cancer Inst 98 273 284 1:CAS:528:DC%2BD28Xhs1Skt78%3D 16478746
57. M. Ozguroglu B. Arun G. Demir, et al. 2000 Serum erythropoietin level in anemic cancer patients Med Oncol 17 29 34 10.1007/BF02826213 1:STN:280:DC%2BD3c7otVegsQ%3D%3D 10713657
58. A.C. Heatherington J. Glaspy D. Kotasek, et al. 2001 Changes endogenous erythropoietin and the pharmacokinetics of darbepoetin alfa in patients with non-myeloid malignancies receiving chemotherapy Blood 98 298a 299a
59. B. Kaczorowska-Hac A. Balcerska 2003 Endogenous erythropoietin levels in children with malignant disorders Acta Haematologica Polonica 34 231 237
60. M. González-Barón A. Ordóñez R. Franquesa, et al. 2002 Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy Cancer 95 2408 2413 10.1002/cncr.10980 12436449 (Pubitemid 35351149)
61. T. Fjornes G.J. Wiedemann K. Sack W. Jelkmann 1998 Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy Oncol Rep 5 81 86 1:CAS:528:DyaK1cXltVWgtA%3D%3D 9458299
62. M. Auerbach H. Ballard J.R. Trout, et al. 2004 Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial J Clin Oncol 22 1301 1307 10.1200/JCO.2004.08.119 1:CAS:528:DC%2BD2cXpsVGktbk%3D 15051778 (Pubitemid 41079845)
63. D.H. Henry N.V. Dahl M. Auerbach, et al. 2007 Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy Oncologist 12 231 242 10.1634/theoncologist.12-2-231 1:CAS:528:DC%2BD2sXjtFChsb4%3D 17296819 (Pubitemid 46271625)
64. M. Hedenus G. Birgegård P. Näsman, et al. 2007 Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study Leukemia 21 627 632 1:CAS:528:DC%2BD2sXjt1Wktbk%3D 17252006
65. C. Lerchenmüller F. Husseini B. Gaede, et al. 2006 Intravenous iron supplementation in patients with chemotherapy-induced anemia receiving darbepoetin alpha every 3 weeks: iron parameters in a randomized controlled trial Blood 108 445
66. A. Engert 2005 Recombinant human erythropoietin in oncology: current status and further developments Ann Oncol 16 1584 1595 10.1093/annonc/mdi307 1:STN:280:DC%2BD2MvpvFGquw%3D%3D 15958437 (Pubitemid 41510131)
67. R. Pirker 2007 Safety considerations for erythropoietin treatment in patients with cancer Expert Opin Drug Saf 6 63 69 10.1517/14740338.6.1.63 1:CAS:528:DC%2BD28XhtlGqtr7J 17181453 (Pubitemid 46138609)
68. M. Henke R. Laszig C. Rübe, et al. 2003 Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 1255 1260 10.1016/S0140- 6736(03)14567-9 1:CAS:528:DC%2BD3sXot1Cjt7o%3D 14575968 (Pubitemid 37324251)
69. J.R. Wright Y.C. Ung J.A. Julian, et al. 2007 Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia J Clin Oncol 25 1027 1032 10.1200/JCO.2006.07.1514 1:CAS:528:DC%2BD2sXksVyrsrc%3D 17312332 (Pubitemid 46596751)
70. B. Coiffier M. Boogaerts M. Aapro, et al. 2006 Effect of treatment with epoetin beta on thromboembolic events in anaemic patients with cancer: a meta-analysis Supportive Cancer Ther 4 49 55 10.3816/SCT.2006.n.031 1:CAS:528:DC%2BD2sXktFKqtL8%3D (Pubitemid 44775954)
71. M. Aapro B. Coiffier J. Dunst, et al. 2006 Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis Br J Cancer 95 1467 1473 10.1038/sj.bjc.6603481 1:CAS:528:DC%2BD28Xht1CntrrM 17117175 (Pubitemid 44867480)
72. H. Frommhold R. Guttenberger M. Henke 1998 The impact of blood hemoglobin content on the outcome of radiotherapy The Freiburg experience. Strahlenther Onkol 174 [Suppl4] 31 34
73. A. Obermair E. Petru G. Windbichler, et al. 2000 Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer Oncol Rep 7 639 644 1:STN:280:DC%2BD3c3jt1Wmtg%3D%3D 10767382
74. T. Littlewood F. Mandelli 2002 The effects of anemia in hematologic malignancies: more than a symptom Semin Oncol 29 [3Suppl8] 40 44 12082653
75. A. Bottini A. Berruti M.P. Brizzi, et al. 2003 Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer Br J Cancer 89 977 982 10.1038/sj.bjc.6601216 1:CAS:528:DC%2BD3sXntVKgu7s%3D 12966412 (Pubitemid 37239198)
76. L.B. Harrison M. Chadha R.J. Hill, et al. 2002 Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 7 492 508 10.1634/theoncologist.7-6-492 12490737 (Pubitemid 36008998)
77. M. Grogan G.M. Thomas I. Melamed, et al. 1999 The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix Cancer 86 1528 1536 10.1002/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E 1:STN:280:DC%2BD3c%2FhtVSjsQ%3D%3D 10526282 (Pubitemid 29489787)
78. C.M. Glaser W. Millesi G.V. Kornek, et al. 2001 Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int J Radiat Oncol Biol Phys 50 705 715 1:CAS:528: DC%2BD3MXktVOitb0%3D 11395239 (Pubitemid 32519598)
79. M. Hedenus S. Hansen K. Taylor, et al. 2002 Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies Br J Haematol 119 79 86 10.1046/j.1365-2141.2002.03774.x 1:CAS:528:DC%2BD38XovFGqtLc%3D 12358906 (Pubitemid 35176501)
80. V. Alymara F. Kouskou P. Bouranta, et al. 2004 Clinical evaluation of once weekly dosing of epoetin alpha in multiple myeloma patients: improvements in hemoglobin are similar to three-timesweekly dosing Hematol J 5 [S272] abstr 815
81. D. Shasha D. Williams 2004 Epoetin alfa 40,000 IU QW increases Hb and is safe in anemic patients not receiving chemotherapy or radiation therapy Blood 104 A4223
82. D. Shasha D.H. Henry 2005 Hematopoietic response to extended dosing of epoetin alfa 60,000 IU every 2 weeks in anemic cancer patients not receiving therapy: final results Blood 106 A3764
83. R. Baz C. Brand E. McGowan, et al. 2005 High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma J Clin Oncol 23 [Suppl16] 6621
84. J. Bogdanos D. Karamanolakis K. Milathianakis, et al. 2004 Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases Anticancer Res 24 1957 1961 1:CAS:528: DC%2BD2cXmsV2juro%3D 15274384
85. Nowrusian MR Voigtman R (2003) Treatment with epoetin beta corrects anemia and decreases transfusion use in patients with solid tumours or haematological malignancies. Eur J Cancer [Suppl 1]:S176, abstr 581
86. V. Charu C.P. Belani A.N. Gill, et al. 2004 A controlled, randomized, open-label study to evaluate the effect of every two week darbepoetin alfa for anemia of cancer J Clin Oncol 22 [Suppl14] 8084
87. M. Hedenus J. Vansteenkiste D. Kotasek, et al. 2005 Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials J Clin Oncol 23 6941 6948 10.1200/JCO.2005.03.434 1:CAS:528:DC%2BD2MXhtFCrsbvL 16192582 (Pubitemid 46260280)
88. E. Katodritou M. Speletas K. Zervas, et al. 2005 Novel hematologic markers for predicting response to r-HuEPO in anemic patients with multiple myeloma and lymphoma Hematol J 90 [Suppl2] S187
89. J. Bohlius J. Wilson J. Seidenfeld, et al. 2006 Erythropoietin or darbepoetin for patients with cancer Cochrane Database Syst Rev 3 CD003407 1:STN:280:DC%2BD28vivFaqsw%3D%3D 16856007
90. R. Abels 1993 Erythropoietin for anemia in cancer patients Eur J Cancer 29A [Suppl2] 2 8 10.1016/S0959-8049(05)80281-3
91. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes 1998 A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes Br J Haematol 103 1070 1074 10.1046/j.1365-2141.1998.01085.x (Pubitemid 29012646)
92. R.E. Smith N.S. Tchekmedyian D. Chan, et al. 2003 A dose-and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer Br J Cancer 88 1851 1858 10.1038/sj.bjc.6600994 1:CAS:528: DC%2BD3sXksVKjtb0%3D 12799626 (Pubitemid 36829658)
93. J.A. Thompson D.G. Gilliland J.T. Prchal, et al. 2000 Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome GM/EPO MDS Study Group. Blood 95 1175 1179 1:CAS:528: DC%2BD3cXhtFKisbo%3D
94. Glaspy J, Smith R, Aapro M et al (2007) Results from a phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. Proc Am Assoc Cancer Res abstract LB-3
95. M. Henke R. Guttenberger A. Barke, et al. 1999 Erythropoietin for patients undergoing radiotherapy: a pilot study Radiother Oncol 50 185 190 10.1016/S0167-8140(98)00115-7 1:CAS:528:DyaK1MXht1Oksbg%3D 10368042 (Pubitemid 29155544)
96. D. Rades S.E. Schild E.F. Yekebas, et al. 2005 Epoetin-alpha during radiotherapy for stage III esophageal carcinoma Cancer 103 2274 2279 10.1002/cncr.21042 1:CAS:528:DC%2BD2MXlsFSnt7o%3D 15852356 (Pubitemid 40686571)
97. D. Antonadou N. Throuvalas R. Lavey, et al. 2003 Final results of a randomized II study evaluating the role of erythropoietin during radiochemotherapy for pelvic tumors Eur J Cancer Suppl 1 279 10.1016/S1359-6349(03)90953-0